HOWL stock forecast, quote, news & analysis
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions... Show more
Why Werewolf Therapeutics (HOWL) Stock Is Up +120% in the Last 30 Days
Key Takeaways
- Werewolf Therapeutics (HOWL) shares have surged roughly 120% over the last 30 days, climbing from around $0.45 in late July to recent trading near $1.00.
- The primary catalyst was an announced all-stock merger with Ambros Therapeutics, plus a concurrent oversubscribed $150 million private placement.
- The combined company is expected to trade on Nasdaq under the ticker "AMBX," with the deal targeted to close in the first quarter of 2027.
- Ambros brings neridronate, a Phase 3 investigational therapy for complex regional pain syndrome (CRPS-1), a condition with no FDA-approved treatment.
- Analyst consensus on HOWL stands at a "Moderate Buy," with three Strong Buy ratings and two Hold ratings among five covering analysts.
Werewolf Therapeutics (HOWL) Company Overview and Market Position
Werewolf Therapeutics is a clinical-stage biopharmaceutical company pioneering conditionally activated therapeutics designed to stimulate the body's immune system against cancer and other immune-mediated conditions. Its proprietary PREDATOR platform underpins INDUKINE molecules intended to remain inactive in peripheral tissue and activate selectively in the tumor microenvironment. The company's most advanced candidates are WTX-124 and WTX-330, systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) molecules for solid tumors, along with earlier-stage INDUCER programs targeting STEAP1 and CDH6. As a pre-revenue developer, Werewolf has been closely followed for its clinical data, cash position, and strategic alternatives rather than for product sales.
Werewolf Therapeutics (HOWL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, HOWL has moved sharply higher. Shares closed near $0.45 on July 27, 2026, and have since climbed to a recent close of approximately $0.89, with intraday trading reaching the $1.00 level — an advance of roughly 120%. The move was compressed into a short window: for much of the period, the stock traded in a range between roughly $0.30 and $0.50 before the August 21 merger announcement triggered a dramatic repricing on exceptionally heavy volume.
Over the last quarter, the stock was largely rangebound in the low $0.30s to low $0.40s through most of the period, briefly touching around $0.50 in late July before retreating. Nearly the entirety of the stock's quarterly gain was generated in the final trading sessions of the period following the merger and financing announcements, underscoring how event-driven this advance has been.
What Drove HOWL Stock Price in the Last 30 Days
The dominant catalyst was Werewolf's August 21, 2026 announcement of an all-stock merger agreement with Ambros Therapeutics. The combined entity is expected to operate as Ambros Therapeutics and trade under the ticker "AMBX" on Nasdaq, with closing targeted for the first quarter of 2027. Ambros' lead program, neridronate, is in a pivotal Phase 3 trial for warm CRPS-1 and has received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations.
Alongside the merger, the companies disclosed an oversubscribed $150 million private placement led by RA Capital Management and Janus Henderson Investors, with additional participation from healthcare-focused investors. Management expects the proceeds to fund the combined company through top-line Phase 3 results and a potential regulatory filing, extending cash runway into the first half of 2029.
Additional developments reinforced the narrative. Werewolf reported a second-quarter net profit of $3.7 million, driven by $21 million in collaboration revenue from the sale of its JZP898 program to Jazz Pharmaceuticals (JAZZ), and separately disclosed an asset purchase agreement with EMD Serono covering preclinical programs. These transactions improved the balance sheet and clarified the company's strategic direction, contributing to the surge in investor enthusiasm.
What Drove HOWL Stock Performance Over the Last Quarter
The broader quarterly trend was defined by strategic repositioning. Entering the period, Werewolf was a cash-constrained clinical-stage biotech evaluating strategic alternatives with advisor Piper Sandler. The company monetized non-core assets — selling the JZP898 program to Jazz and its preclinical INDUCER platform to EMD Serono — while repaying all debt under its K2 HealthVentures loan agreement. These steps strengthened the balance sheet but left the company's long-term direction uncertain.
The merger with Ambros resolved much of that uncertainty by pairing Werewolf's oncology pipeline with a late-stage, well-funded clinical asset. The transaction reframed HOWL as a vehicle for exposure to a Phase 3 program addressing an unmet medical need, which is why the stock's quarterly performance ultimately concentrated around the merger announcement rather than spreading across the period.
Trending AI Robots
For investors tracking momentum across the market, Tickeron's Trending AI Robots page offers a curated view of top-performing automated trading strategies. Tickeron provides hundreds of AI trading bots that trade thousands of tickers, but only the most relevant and best-performing bots are featured in this section. These bots vary in strategy, timeframe, and performance metrics, giving traders a range of approaches to evaluate. Browsing the trending selection can help identify which AI-driven strategies are currently generating attention and results across the market.
HOWL Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term factor is the completion of the Ambros merger, which remains subject to shareholder approval and customary closing conditions. Investors should monitor regulatory filings, including the Form S-4 registration statement, for details on the transaction's terms and timeline. Clinical updates on neridronate's pivotal Phase 3 CRPS-RISE trial and top-line data expectations will be central to the combined company's valuation.
Beyond the merger, key considerations include Werewolf's planned data updates for WTX-124 and WTX-330 in the second half of 2026, the successful completion of the private placement, and the integration of the two pipelines. As a penny stock, HOWL remains subject to elevated volatility, and risks tied to clinical outcomes, regulatory review, and financing execution should be weighed carefully.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HOWL in upward trend: 10-day moving average crossed above 50-day moving average on July 29, 2026
The 10-day moving average for HOWL crossed bullishly above the 50-day moving average on July 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 19, 2026. You may want to consider a long position or call options on HOWL as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for HOWL just turned positive on August 18, 2026. Looking at past instances where HOWL's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
HOWL moved above its 50-day moving average on August 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HOWL advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 126 cases where HOWL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HOWL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HOWL broke above its upper Bollinger Band on August 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.964) is normal, around the industry mean (20.583). P/E Ratio (0.000) is within average values for comparable stocks, (27.923). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.559). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.303) is also within normal values, averaging (443.835).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HOWL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HOWL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology